OverviewSuggest Edit
Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
| Type | Public | |
| Founded | 1996 | |
| HQ | Basel, CH | Map |
| Website | novartis.com | |
| Employee Ratings | More | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others
- Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma
- Global $12.7 Billion Pharmacogenomics Markets to 2026 with Profiles of Abbott Laboratories, GlaxoSmithKline, Johnson & Johnson, Novartis, Oxford Nanopore Technologies and Thermo Fisher Scientific
- KT, 한국노바티스와 디지털·바이오헬스 사업 협력
Key People/Management at Novartis
Vasant Narasimhan
Chief Executive Officer
Joerg Reinhardt
Chairman
Steven Baert
Chief People & Organization Officer
James Bradner
President of the Novartis Institutes for BioMedical Research (NIBR)
Thomas N. Kendris
Ad Interim Chief Legal Officer of Novartis
Karen L. Hale
Chief Legal Officer
Novartis Office Locations
Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Pratteln, CH
Schweizerhalle, Rheinstrasse 52
Stein, CH
Schaffhauserstrasse 101
Tirana, AL
Rruga Hoxha Tahsim 23
Bir Mourad Raïs, DZ
69 Zone d´Activité Said Hamdine
Novartis Financials and Metrics
Novartis Revenue
Novartis's revenue was reported to be $48.66 b in FY, 2020 which is a 2.6% increase from the previous period.
| USD | |
|---|---|
Revenue (FY, 2020) | 48.7b |
Revenue growth (FY, 2019 - FY, 2020), % | 2.6% |
Gross profit (FY, 2020) | 33.5b |
Gross profit margin (FY, 2020), % | 68.9% |
Net income (FY, 2020) | 8.1b |
EBIT (FY, 2020) | 10.2b |
Market capitalization (14-May-2021) | 179.7b |
Closing stock price (14-May-2021) | 80.5 |
Cash (31-Dec-2020) | 9.7b |
EV | 208.1b |
Novartis's current market capitalization is CHF179.7 b.
- Source: Company Filings
Annual
- Source: Company Filings
Annual
- Source: Company Filings
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 2.0b | 9.8b | 11.4b | 1.9b | 4.0b | 6.0b | 2.2b | 4.0b | 6.0b |
Depreciation and Amortization | 4.9b | 1.4b | 2.5b | 3.9b | 1.4b | 3.1b | |||
Cash From Operating Activities | 2.5b | 6.5b | 10.5b | 2.4b | 5.5b | 10.1b | 2.5b | 6.5b | 9.6b |
Purchases of PP&E | (359.0m) | (690.0m) | (1.1b) | (282.0m) | (561.0m) | (918.0m) | (237.0m) | (475.0m) | (754.0m) |
- Source: Company Filings
| USD | Q1, 2018 |
|---|---|
Debt/Equity | 0.5 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.9 x |
Novartis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Vedere Bio | October 29, 2020 | $280 m |
| Amblyotech | April 21, 2020 | |
| The Medicines Company | November 25, 2019 | $9.7 b |
| Xiidra | May 09, 2019 | $1.9 b |
| Novartis Inflammasome Research | April 02, 2019 | $1.58 b |
| CellforCure | December 21, 2018 | |
| Endocyte | October 18, 2018 | |
| AveXis | April 09, 2018 | $8.7 b |
| Advanced Accelerator Applications | October 30, 2017 | $3.9 b |
| Encore Vision | December 20, 2016 |
Novartis Revenue Breakdown
Novartis revenue breakdown by business segment: 19.8% from Sandoz and 80.2% from Innovative Medicines
Novartis revenue breakdown by geographic segment: 5.3% from China, 5.8% from Japan , 33.9% from United States, 5.0% from France, 9.3% from Germany and 40.8% from Other
Novartis Cybersecurity Score
Novartis Environment, Social & Governance (ESG) Ratings
Novartis Online and Social Media Presence
292.8k Twitter followers
Novartis has 292.8k Twitter Followers. The number of followers has increased 0.5% month over month and increased 1.9% quarter over quarter
Novartis's Trends
Twitter Engagement Stats for @novartis
12.5k
Tweets
567
Following
292.8k
Followers
21
Tweets last 30 days
11.5
Avg. likes per Tweet
66.7%
Tweets with engagement
Novartis Company Culture
Overall Culture
A+
84/100
CEO Rating
A+
80/100
Compensation
A+
93/100
Diversity
A+
83/100
Novartis News and Updates
May 13, 2021
Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
May 13, 2021
Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Corticosteroids Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson …
May 11, 2021
Global $12.7 Billion Pharmacogenomics Markets to 2026 with Profiles of Abbott Laboratories, GlaxoSmithKline, Johnson & Johnson, Novartis, Oxford Nanopore Technologies and Thermo Fisher Scientific
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "Global Pharmacogenomics Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
May 10, 2021
KT, 한국노바티스와 디지털·바이오헬스 사업 협력
KT가 디지털·바이오헬스산업의 디지털전환(DX) 본격화에 나선다. KT(대표 구현모)는 한국노바티스와 서울 종로구 KT 광화문 EAST사옥에서 디지털·바이오헬스 사업 협력을 위한 업무협약(MOU)을 체결했다고 10일 발표했다.
May 06, 2021
Global Ai In Pharma Market Report 2021: Long-term Forecast to 2025 & 2030 Featuring Novartis, IBM Watson, Microsoft, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Exscientia, and Cyclica
DUBLIN, May 6, 2021 /PRNewswire/ -- The "AI In Pharma Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report focuses on Ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in...
May 01, 2021
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best correcte…
Novartis Frequently Asked Questions
When was Novartis founded?
Novartis was founded in 1996.
Who are Novartis key executives?
Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Steven Baert.
How many employees does Novartis have?
Novartis has 105,794 employees.
What is Novartis revenue?
Latest Novartis annual revenue is $48.7 b.
What is Novartis revenue per employee?
Latest Novartis revenue per employee is $459.9 k.
Who are Novartis competitors?
Competitors of Novartis include Bausch + Lomb, Immunomedics and Gilead Sciences.
Where is Novartis headquarters?
Novartis headquarters is located at Fabrikstrasse 2, Basel.
Where are Novartis offices?
Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations.
How many offices does Novartis have?
Novartis has 185 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies